Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions

Study to evaluate the change of health-related quality of life, patient characteristics, efficacy and safety in Chronic Obstructive Pulmonary Disease (COPD) patients with Dupilumab therapy in a real-world setting over 24 months.

NCT Number	NCT07052396
Lead Sponsor	Sanofi Collaborators: Regeneron Pharmaceuticals
Conditions	Chronic Obstructive Pulmonary Disease (COPD)
Enrollment	350 participants
Start Date	2025-07-01
Primary Completion	2029-07-01 (estimated)
Study Completion	2029-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-22